Short answer
CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). CRISPR Therapeutics reported financial results for quarter ended March 31, 2026.
CRISPR Therapeutics AG 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- CRISPR Therapeutics reported financial results for quarter ended March 31, 2026
- Business highlights accompanied quarterly results, with full details in Exhibit 99.1
- Press release furnished under Item 2.02, limiting Section 18 Exchange Act liability and automatic incorporation by reference
Item EX-99.1 · Exhibit EX-99.1
- CASGEVY revenue reached $43 million in Q1 2026, with more than 500 patients initiating treatment globally
- Cash, equivalents and marketable securities rose to $2,441.8 million, bolstered by $585.4 million convertible-note proceeds
- Net loss narrowed to $122.9 million from $136.0 million, while R&D expense declined to $68.6 million
- Zugo-cel autoimmune trials dosed over 14 patients across SSc, IM and SLE, with further updates expected in the second half of 2026
- Multiple pipeline catalysts expected in 2026, including CTX460 and CTX340 clinical-trial initiations and CTX310 development updates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CRISPR Therapeutics AG 8-K filings
Get the next CRSP 8-K as it lands
Follow CRSP for push alerts, or ask the research agent what this filing means.